{"Importance": [0], "Approximately": [1], "125": [2], "million": [3], "people": [4], "worldwide": [5], "have": [6, 43], "psoriasis.": [7, 35, 256], "Patients": [8], "with": [9, 57, 71, 238], "psoriasis": [10, 28, 42, 54, 114, 221, 264], "experience": [11], "substantial": [12], "morbidity": [13], "and": [14, 22, 50, 67, 81, 91, 122, 138, 153, 160, 162, 171, 178, 199, 227, 241, 272], "increased": [15], "rates": [16], "of": [17, 34, 60, 79, 96, 109, 116, 149, 166, 186, 246], "inflammatory": [18, 232], "arthritis,": [19, 64], "cardiometabolic": [20, 65], "diseases,": [21, 66], "mental": [23], "health": [24], "disorders.": [25], "Observations": [26], "Plaque": [27, 53], "is": [29, 55, 206, 222, 230, 236], "the": [30, 77, 146, 150, 163, 184, 200, 251], "most": [31, 37, 212], "common": [32], "variant": [33], "The": [36, 93, 211], "rapid": [38], "advancements": [39, 258], "addressing": [40], "plaque": [41, 113, 220, 263], "been": [44], "in": [45, 119], "its": [46], "pathogenesis,": [47], "genetics,": [48], "comorbidities,": [49], "biologic": [51], "treatments.": [52], "associated": [56, 237], "a": [58, 207], "number": [59], "comorbidities": [61, 240], "including": [62], "psoriatic": [63, 187], "depression.": [68], "For": [69], "patients": [70], "mild": [72, 255], "psoriasis,": [73], "topical": [74, 84], "agents": [75, 193], "remain": [76, 250], "mainstay": [78], "treatment,": [80], "they": [82], "include": [83, 134, 191, 265], "corticosteroids,": [85], "vitamin": [86], "D": [87], "analogues,": [88], "calcineurin": [89], "inhibitors,": [90], "keratolytics.": [92], "American": [94], "Academy": [95], "Dermatology-National": [97], "Psoriasis": [98, 229], "Foundation": [99], "guidelines": [100], "recommend": [101], "biologics": [102, 141, 266], "as": [103, 145, 195, 274, 276], "an": [104, 231, 277], "option": [105], "for": [106, 183, 253, 259], "first-line": [107], "treatment": [108, 185], "moderate": [110, 260], "to": [111, 128, 218, 261], "severe": [112, 262], "because": [115], "their": [117], "efficacy": [118], "treating": [120, 254], "it": [121], "acceptable": [123], "safety": [124], "profiles.": [125], "Specifically,": [126], "inhibitors": [127], "tumor": [129], "necrosis": [130], "factor": [131], "\u03b1": [132], "(TNF-\u03b1)": [133], "etanercept,": [135], "adalimumab,": [136], "certolizumab,": [137], "infliximab.": [139], "Other": [140], "inhibit": [142, 175, 268], "cytokines": [143, 151], "such": [144, 194], "p40": [147], "subunit": [148, 165], "IL-12": [152], "IL-23": [154, 167], "(ustekinumab),": [155], "IL-17": [156, 179], "(secukinumab,": [157], "ixekizumab,": [158], "bimekizumab,": [159], "brodalumab),": [161], "p19": [164], "(guselkumab,": [168], "tildrakizumab,": [169], "risankizumab,": [170], "mirikizumab).": [172], "Biologics": [173], "that": [174, 235, 267], "TNF-\u03b1,": [176, 269], "p40IL-12/23,": [177, 270], "are": [180], "also": [181], "approved": [182], "arthritis.": [188], "Oral": [189], "treatments": [190], "traditional": [192], "methotrexate,": [196], "acitretin,": [197], "cyclosporine,": [198], "advanced": [201], "small": [202], "molecule": [203], "apremilast,": [204], "which": [205], "phosphodiesterase": [208, 279], "4": [209, 280], "inhibitor.": [210, 281], "commonly": [213], "prescribed": [214], "light": [215], "therapy": [216], "used": [217], "treat": [219], "narrowband": [223], "UV-B": [224], "phototherapy.": [225], "Conclusions": [226], "Relevance": [228], "skin": [233], "disease": [234], "multiple": [239], "substantially": [242], "diminishes": [243], "patients\u2019": [244], "quality": [245], "life.": [247], "Topical": [248], "therapies": [249], "cornerstone": [252], "Therapeutic": [257], "IL-17,": [271], "p19IL-23,": [273], "well": [275], "oral": [278]}